Do not miss scheduled appointments or change the frequency
The FDA announced the action on April 15, 2026 (Federal Register notice April 16), and the peptides come off the Category 2 list effective April 23, 2026
Common Protocol: MK-677: 12.525 mg daily, oral, taken at night BPC-157: 250500 mcg daily, subcutaneous Cycle: 812 weeks for MK-677
This is one of the most important parts of the conversation
These therapies are prescribed only after a thorough medical evaluation and discussion of potential risks, benefits, and alternatives
For scalp hair, well-formulated topical application, especially paired with microneedling, is the evidence-supported approach